Amgen Inc. (AMGN) Given Consensus Rating of “Buy” by Brokerages
Shares of Amgen Inc. (NASDAQ:AMGN) have been assigned a consensus recommendation of “Buy” from the twenty-three ratings firms that are covering the company, Marketbeat.com reports. Ten analysts have rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $187.81.
A number of brokerages have issued reports on AMGN. Royal Bank Of Canada began coverage on Amgen in a research report on Thursday, September 14th. They set a “sector perform” rating and a $192.00 price target on the stock. BMO Capital Markets reiterated a “hold” rating and set a $199.00 price target on shares of Amgen in a research report on Monday, September 25th. Jefferies Group LLC reiterated a “buy” rating and set a $200.00 price target on shares of Amgen in a research report on Monday, September 25th. Mizuho reiterated a “buy” rating and set a $198.00 price target (up previously from $183.00) on shares of Amgen in a research report on Thursday, September 28th. Finally, Credit Suisse Group reiterated a “neutral” rating and set a $186.00 price target (up previously from $177.00) on shares of Amgen in a research report on Friday, September 29th.
Amgen (NASDAQ AMGN) traded up 0.73% on Wednesday, hitting $188.59. The stock had a trading volume of 1,660,280 shares. Amgen has a 12 month low of $133.64 and a 12 month high of $191.10. The company’s 50 day moving average is $180.38 and its 200-day moving average is $169.99. The stock has a market cap of $137.61 billion, a P/E ratio of 17.18 and a beta of 1.36.
Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. The firm had revenue of $5.81 billion for the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The company’s revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.84 earnings per share. Analysts forecast that Amgen will post $12.57 EPS for the current year.
The company also recently declared a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Thursday, August 17th were given a dividend of $1.15 per share. The ex-dividend date of this dividend was Tuesday, August 15th. This represents a $4.60 annualized dividend and a dividend yield of 2.44%. Amgen’s dividend payout ratio is currently 41.93%.
Several institutional investors and hedge funds have recently added to or reduced their stakes in AMGN. TrimTabs Asset Management LLC boosted its position in shares of Amgen by 88.9% during the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock worth $100,000 after buying an additional 288 shares during the period. Alpha Omega Wealth Management LLC boosted its position in shares of Amgen by 19.0% during the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock worth $103,000 after buying an additional 100 shares during the period. Jackson Grant Investment Advisers Inc. boosted its position in shares of Amgen by 0.6% during the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after buying an additional 4 shares during the period. American Beacon Advisors Inc. purchased a new position in shares of Amgen during the first quarter worth $106,000. Finally, Phocas Financial Corp. purchased a new position in shares of Amgen during the second quarter worth $110,000. Institutional investors and hedge funds own 78.10% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.